Hints and tips:
...survival for those with non-small cell lung cancer that has spread elsewhere in the body will not now be released until the second half of the year, the company and its global biologics and development arm, MedImmune...
...The Anglo-Swedish drugmaker, and MedImmune, its global biologics research and development arm, announced that the US Food and Drug Administration (FDA) had accepted the licence application for moxetumomab...
...Dr Jean-Charles Soria will join MedImmune as head of oncology for innovative medicines, while Dr Geoffrey Kim has been appointed as head of oncology for strategic combinations at AstraZeneca....
...Cambridge-based MedImmune accounts for neatly half of AstraZeneca’s overall R&D portfolio....
...AstraZeneca and MedImmune would have the right to commercialise any successful products....
...Bahija Jallal, executive vice-president of MedImmune, said: “The cutting-edge technologies developed by Spirogen and ADC Therapeutics complement MedImmune’s innovative antibody engineering capabilities,...
...His last big acquisition, the $15bn purchase of Medimmune in 2007, has not halted the decline. Perhaps he feels burned by the experience....
...Its efforts to accelerate progress through the acquisition of CAT in 2006 and MedImmune in 2007 both backfired, with few of those companies’ planned drugs since making significant advances....
...His record of doing such mega deals is questionable, as the $15.6bn takeover of US biotechnology company Medimmune in 2007 has failed to produce many new drugs and is considered a flop....
...Capital Advisors, one of the nation’s most successful hedge funds, is a focus of an SEC investigation into whether traders used inside information to profit from the $15bn takeover of biotechnology firm MedImmune...
...However, Mr Justice Arnold rejected the claim brought by MedImmune against Novartis on Lucentis, concluding in a 261-page judgment: “As MedImmune concedes, it follows that both patents are invalid.”...
...The company lifted its full-year core earnings target by 5 cents a share to $6.95-$7.25, reflecting the recent settlement of a patent dispute between MedImmune and PDL Biopharma that added $131m to its...
...The FTSE 100 group had acquired motavizumab as part of the $15.6bn deal to buy Medimmune, a US biotechnology business, in 2007....
...Stephen Goldfield profited from illegal trading ahead of the $15.6bn takeover of MedImmune, the US biotech business, by Anglo-Swiss group AstraZeneca, the SEC alleged in a federal court filing....
...It said Mr Self, as part of the team that submitted an unsuccessful bid for MedImmune, was privy to confidential information about the sale of the company....
...Problems in producing the vaccine slowed its manufacture for several companies, while others such as MedImmune, a division of AstraZeneca supplying the US, has been unable to speedily produce in sufficient...
...The company booked $152m of $453m in an order from the US government for 40m doses of the live attenuated pandemic flu vaccine made by its subsidiary MedImmune, which received approved from regulators last...
...Meanwhile, its $15bn purchase of MedImmune in 2007 gave it a large presence in higher-margin “large molecule” therapies....
...MedImmune, which is now part of AstraZeneca, Baxter, CSL and Solvay are also being sent samples, as are smaller developers Microgen, Nobilon International, Omnivest Vaccines and Vivaldi....
...Mr Frante will be named president of the US, while Mr Zook is president and chief executive for North America, as well as president of MedImmune, the biological medicines division of the company....
...Sales from MedImmune of the US, acquired last year, helped offset declines from Toprol XR and there was strong growth in emerging markets, notably in Asia....
...There are other pluses for Astra, which has been in the doghouse since last year’s $15bn pricey purchase of biotechnology company MedImmune....
...The £7.7bn acquisition of MedImmune and stronger emerging markets helped push sales 10 per cent higher than the first quarter last year to $7.7bn, and allowed AstraZeneca to raise 2008 core earnings per...
...Last year AstraZeneca paid $15.6bn for MedImmune the US drugs specialist in cardiovascular treatment....
...Mr Brennan said the purchase of MedImmune and other efforts to revamp its pipeline of experimental medicines meant it should beat targets by launching two new molecular entities a year by 2010 instead of...
International Edition